nach oben

Journal of Neural Transmission

Erschienen in:

23.01.2020 | Neurology and Preclinical Neurological Studies - Review Article

The discovery and development of rasagiline as a new anti-Parkinson medication

verfasst von: John P. M. Finberg

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Excerpt

The following is a much abridged description of the background to the joint pharmacological studies between myself and Moussa Youdim which formed most of the preclinical work leading to the development of the selective monoamine oxidase type B inhibitor rasagiline as a treatment for Parkinson’s disease. …

In this reference, the value for chronic clorgyline DA basal level should be 0.9 and not 0.09

Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525(1):36–44CrossRef

Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1(8009):439–443CrossRef

Finberg JPM (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143(2):133–152CrossRef

Finberg JPM, Tenne M (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77(1):13–21CrossRef

Finberg JPM, Youdim MBH (1985) Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol 85(2):541–546CrossRef

Finberg JPM, Youdim MBH (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacol 43:1110–1118CrossRef

Finberg JPM, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73(1):65–74CrossRef

Fowler CJ, Ross SB (1984) Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties. Med Res Revs 4(3):323–358CrossRef

Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49(1–2):1–20CrossRef

Gillman PK, Feinberg SS, Fochtmann LJ (2019) Revitalizing monoamine oxidase inhibitors: a call for action. CNS Spectr 1–3

Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265(5589):80–81CrossRef

Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17(7):1285–1297CrossRef

Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73(1):55–64CrossRef

Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408PubMed

Lader MH, Sakalis G, Tansella M (1970) Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 18(1):118–123CrossRef

Laine K, Anttila M, Huupponen R, Maki-IkolaIkola O, Heinonen E (2000) Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 23(1):22–27CrossRef

Lamensdorf I, Youdim MBH, Finberg JPM (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67(4):1532–1539CrossRef

Panniset M, Chen JJ, Rhyee SH, Conner J, Mathena J (2014) Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacother 34(12):1250–1258CrossRef

Perez-Lloret S, Rascol O (2011) Safety of rasagiline for the treatment of Parkinson's disease. Exp Opin Drug Saf 10(4):633–643CrossRef

Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with l-deprenyl. J Neurochem 46:1359–1365CrossRef

Sader-Mazbar O, Loboda Y, Rabey MJ, Finberg JPM (2013) Increased L-dopa-derived dopamine following selective MAO-A or-B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Br J Pharmacol 170(5):999–1013CrossRef

Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G et al (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62(1):15–30CrossRef

Thebault JJ, Guillaume M, Levy R (2004) Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacother 24(10):1295–1305CrossRef

Tipton KF, Youdim MBH (1983) The assay of monoamine oxidase activity. In: Parvez S, Nagatsu T, Nagatsu I, Parvez H (eds) Methods in biogenic amine research. Elsevier, Amsterdam, pp 441–467

Yang HY, Neff NH (1974) The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189(3):733–740PubMed

Youdim MBH, Finberg JPM (1983). Monoamine oxidase inhibitor antidepressants. In: Grahame-Smith DG, Cowen PJ (eds) Part 1: preclinical psychopharmacology. Excerpta Medica, Amsterdam, pp 38–70

Youdim MBH, Finberg J (1985) Monoamine oxidase inhibitor antidepressants. In: Grahame-Smith DG (ed) Psychopharmacology 2: Part 1: preclinical psychopharmacology. Elsevier, Amsterdam, pp 35–70CrossRef

Youdim MBH, Finberg JPM, Tipton KF (1988) Monoamine Oxidase. In: Trendelenburg U, Weiner N (eds) Handbook of experimental pharmacology, vol 90. Springer, Berlin, pp 119–192

Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132(2):500–506CrossRef

Titel: The discovery and development of rasagiline as a new anti-Parkinson medication
verfasst von: John P. M. Finberg
Publikationsdatum: 23.01.2020
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 2/2020
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-020-02142-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The discovery and development of rasagiline as a new anti-Parkinson medication

Excerpt

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Correction to: Hypothesis: neural mechanism of psychotherapy for the treatment of Parkinson’s disease: cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy?

6-Hydroxydopamine: a far from simple neurotoxin

Parkinson’s disease and iron

Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson’s disease

FG 7142: is this validated tool to study anxiety now forgotten?

Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie